Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczemanews2022-01-14T20:56:01+00:00January 14th, 2022|Fierce Pharma|
After delays, Pfizer’s blockbuster-to-be eczema drug Cibinqo snags FDA nodnews2022-01-14T20:56:01+00:00January 14th, 2022|Fierce Pharma|
Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirectionnews2022-01-14T18:21:01+00:00January 14th, 2022|Fierce Pharma|
Emergent BioSolutions founder El-Hibri bids adieu after CDMO’s turbulent 2021news2022-01-14T16:48:57+00:00January 14th, 2022|Fierce Pharma|
Califf advances in FDA chief nomination process but committee vote indicates he’s no slam-dunk choicenews2022-01-14T16:20:28+00:00January 14th, 2022|Fierce Pharma|
JPM 2022: With Voxzogo approvals adding up, BioMarin is underway with its ‘biggest launch,’ CEO saysnews2022-01-14T15:27:44+00:00January 14th, 2022|Fierce Pharma|
Idorsia makes friends with Jen Aniston for new sleep campaign, as it preps for insomnia drug launchnews2022-01-14T15:20:16+00:00January 14th, 2022|Fierce Pharma|
Idorsia makes friends with Aniston for new sleep campaign as it preps for insomnia drug launchnews2022-01-14T15:20:16+00:00January 14th, 2022|Fierce Pharma|
Biogen compiles buyout target list as Aduhelm woe deepens: Statnews2022-01-14T15:04:32+00:00January 14th, 2022|Fierce Pharma|
US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikesnews2022-01-14T14:33:34+00:00January 14th, 2022|Fierce Pharma|
